AOD-9604: A Tracking Guide for an hGH Fragment

AOD-9604 is a synthetic fragment of human growth hormone, corresponding to residues 177–191. It was developed as a fat-loss drug on the theory that this region carries the lipolytic activity of GH without the growth-promoting, IGF-1-raising effects. It progressed into Phase 2b obesity trials and failed to show meaningful weight loss versus placebo. It remains popular in self-experimenter circles, partly because of that "no IGF-1 effect" framing.

What it is supposed to do

In animal models, AOD-9604 stimulates lipolysis and inhibits lipogenesis. The selling point compared to full GH or GH secretagogues is that it does not appear to meaningfully raise IGF-1 or affect glucose tolerance in short studies. The disappointing piece is that this also seems to limit how much real-world fat loss occurs.

Typical protocol shape

• Route: subcutaneous injection; oral troches also circulate, with uncertain bioavailability
• Frequency: once daily, usually morning fasted
• Dose: self-reports cluster around 250–500 mcg/day; trial doses were in a similar range
• Duration: 8–12 weeks is a common block, sometimes longer

This is a research peptide, not an approved drug in major markets. Source quality varies widely.

What to track daily

• Morning fasted weight
• Waist at the navel, weekly average is more useful than daily noise
• Hunger and satiety ratings
• Energy through the day
• Injection site reactions

What to track weekly

• Body composition by a consistent method
• Waist, hip, thigh, and arm circumferences
• Training performance and recovery
• Sleep quality summary
• Photos in consistent lighting and pose

Bloodwork worth doing

• Baseline and end-of-cycle IGF-1, to confirm the "no IGF-1 effect" claim in your own data
• Fasting glucose and insulin
• Lipid panel
• Liver and kidney panels

Realistic expectations

Trial data and honest self-reports converge on modest effects at best. If you are also in a calorie deficit and training, you will probably see fat loss, and it is genuinely hard to know how much of it the peptide is contributing. If you are not in a deficit, AOD-9604 alone is unlikely to drive visible body composition changes.

Common mistakes

• Starting AOD-9604 at the same time as a new diet, then crediting the peptide for the deficit's effect
• Comparing weekly weight without averaging
• Expecting a GH-like body composition response without the IGF-1 cost — the mechanism that makes it "safer" is the same one that limits its effect size
• Stacking with multiple other fat-loss compounds, which makes any signal unreadable

A tracking template

• Week 0: baseline bloodwork, measurements, photos, two-week food log
• Weeks 1–4: hold diet and training constant; log daily metrics in Peptide IA
• Weeks 5–8: continue, repeat measurements at week 8
• Weeks 9–12: final block, repeat bloodwork and full measurements at week 12
• Weeks 13–16: washout, repeat at week 16

Bottom line

AOD-9604 has a clean mechanistic story and a disappointing clinical record. It is reasonable to test on yourself if you understand that the most likely outcome is "no clearly detectable effect on top of diet and training." Strict baselines, single-variable changes, and a real washout are what let you draw a conclusion either way.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.